समाचार Samāchār · India · 29 October 2026

Cancer drugs get cheaper from 9 November as NPPA reprices 543 brands

The price regulator has published new maximum retail prices after capping trade margins at 30% on 137 anti-cancer drugs. Some brands fall by more than 70%.

Cancer treatment in India gets cheaper in eleven days. The National Pharmaceutical Pricing Authority on Wednesday published revised maximum retail prices for 543 brands of anti-cancer medicines. The new prices apply from 9 November. The list reflects what companies had filed by 27 October. NPPA says it will add brands as more manufacturers submit.

The cuts are steep. A 10-tablet pack of RPG Life Sciences’ anastrozole falls from ₹695.76 to ₹73. Abbott’s bevacizumab 100 mg vial falls from ₹21,767.70 to ₹5,930.13. RPG’s denosumab 60 mg syringe falls from ₹22,031.25 to ₹5,941. Hetero’s fludarabine injection falls from ₹14,235 to ₹2,432. Dr Reddy’s azacitidine falls from ₹6,337 to ₹1,495.04.

The tool was set on 17 October. NPPA capped trade margins at 30% on 137 non-scheduled anti-cancer drugs, under paragraph 19 of the Drugs (Prices Control) Order, 2013. The list came from an expert committee under the Directorate General of Health Services. It includes immunotherapy medicines used for more than 20 types of cancer, along with denosumab, pegfilgrastim and bevacizumab. Prices were expected to fall by up to 70%. The last such cap, in 2019, covered 42 cancer drugs across 526 brands.

The method is the point. The state did not fix a price for each molecule. It went after the gap between what the maker charges and what the patient pays. Makers keep their pricing freedom. The chain loses the excess. It is minimum government with maximum effect. Credit goes to NPPA and the Department of Pharmaceuticals for moving from notification to a published price list in eleven days.

Two tests follow. State drug controllers must make sure every pharmacy and hospital charges the new price, and patients can check it on the Pharma Sahi Daam app. Stock must stay on the shelves. The larger gain is still prevention: a cheaper drug helps a family after diagnosis, while early detection keeps more families from needing it.

What a founder takes from it: Capping the margin rather than the price is the kind of regulation India needs: narrow, fast and measurable. For founders in health, cheaper treatment moves the opportunity upstream to early detection, and downstream to distribution that actually delivers the new price to the patient.